TuHURA Biosciences, Inc.
HURA
$1.81
-$0.03-1.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 124.76% | 31.83% | 139.54% | 128.47% | -28.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.41% | 65.14% | 52.35% | 114.23% | -18.22% |
| Operating Income | -80.41% | -65.14% | -52.35% | -114.23% | 18.22% |
| Income Before Tax | -27.31% | -80.88% | -37.63% | -123.55% | -22.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.31% | -80.88% | -37.63% | -123.55% | -22.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.31% | -80.88% | -37.63% | -123.55% | -22.86% |
| EBIT | -80.41% | -65.14% | -52.35% | -114.23% | 18.22% |
| EBITDA | -81.25% | -66.41% | -53.19% | -116.50% | 18.01% |
| EPS Basic | 73.91% | 50.54% | 61.39% | -259.64% | -- |
| Normalized Basic EPS | 69.40% | 70.80% | 61.38% | -261.22% | -- |
| EPS Diluted | 73.91% | 50.54% | 61.39% | -252.49% | -- |
| Normalized Diluted EPS | 69.40% | 70.80% | 61.38% | -261.22% | -- |
| Average Basic Shares Outstanding | 316.03% | 265.85% | 256.55% | -37.77% | -- |
| Average Diluted Shares Outstanding | 316.03% | 265.85% | 256.55% | -37.77% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |